Finance

Beta
Lists
6Z4:FRA
Crinetics Pharmaceuticals Inc
€28.99
+4.32%
(+1.20) 1D
Jun 5, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 6Z4...
Open
€28.99
High
€28.99
Low
€28.99
Mkt. cap
3.47B
Avg. vol.
27.00
Volume
0.00
52-wk high
€43.40
52-wk low
€23.00
No. of employees
594
Open
€28.99
High
€28.99
Low
€28.99
Mkt. cap
3.47B
Avg. vol.
27.00
Volume
0.00
52-wk high
€43.40
52-wk low
€23.00
No. of employees
594
News stories
From sources across the web
Profile
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018. Wikipedia
About Crinetics Pharmaceuticals Inc
CEO-
Employees594
FoundedNov 18, 2008
Headquarters-
SectorPharmaceutical industry
Websitecrinetics.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.03M
143.00K
6.16M
10.73M
Cost of goods sold
80.30M
90.46M
86.13M
100.28M
Cost of revenue
80.30M
90.46M
86.13M
100.28M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
49.84M
52.26M
53.70M
50.83M
Operating expense
49.84M
52.26M
53.70M
50.83M
Total operating expenses
130.14M
142.73M
139.83M
151.11M
Operating income
-129.11M
-142.59M
-133.67M
-140.38M
Other non operating income
20.00K
-49.00K
-125.00K
-131.00K
EBT including unusual items
-115.64M
-130.09M
-122.64M
-127.84M
EBT excluding unusual items
-115.64M
-130.09M
-122.64M
-127.84M
Income tax expense
-
-
180.00K
-
Effective tax rate
-
-
-0.15%
-
Other operating expenses
-
-
-
-
Net income
-115.64M
-130.09M
-122.82M
-127.84M
Net profit margin
-11,216.00%
-90,972.73%
-1,993.43%
-1,191.03%
Earnings per share
-1.23
-1.38
-1.29
-1.23
Interest and investment income
13.46M
12.54M
11.16M
12.66M
Interest expense
-
-
-
-
Net interest expenses
13.46M
12.54M
11.16M
12.66M
Depreciation and amortization charges
-
-
-
-
EBITDA
-128.15M
-141.57M
-132.67M
-139.22M
Gain or loss from assets sale
23.00K
-
8.00K
20.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer